All Posts By

Smartkarma Daily Briefs

Daily Brief Credit: Morning Views Asia: JSW Infrastructure and more

By | Credit, Daily Briefs

In today’s briefing:

  • Morning Views Asia: JSW Infrastructure, Lippo Malls Indonesia Retail Trust, SK Hynix


Morning Views Asia: JSW Infrastructure, Lippo Malls Indonesia Retail Trust, SK Hynix

By Charles Macgregor

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Equity Bottom-Up: 2024 High Conviction Idea: More Downside for Meituan and more

By | Daily Briefs, Equity Bottom-Up

In today’s briefing:

  • 2024 High Conviction Idea: More Downside for Meituan
  • Water Oasis ( 1161 HK ) FY23 Results: Resilient Set Up For a >10% Yield in FY24
  • Haier Smart Home (6690 HK): Further Expansion of Footprint
  • WuXi AppTec (2359.HK/603259.CH) – How Bad Things Could Be?
  • LICHF: H2FY24 Guided to Be Strong
  • Marvell Industry Analyst Day


2024 High Conviction Idea: More Downside for Meituan

By Eric Chen

  • We don’t consider Douyin an existential threat to Meituan, but we see the company’s growth increasingly be constrained by its business model itself.
  • We believe Meituan will disappoint the market with regard to its bottom line growth in 2024, barring major overhaul of its new initiative businesses.
  • Meituan will have to make tough choice between growth and profitability and either scenario won’t bode well for its valuation. We value the company at RMB410 billion, meaning 18% downside.

Water Oasis ( 1161 HK ) FY23 Results: Resilient Set Up For a >10% Yield in FY24

By Sameer Taneja

  • Water Oasis (1161 HK) reported 16%/65% YoY revenue/PAT growth for FY23. For H2 FY23 revenue/PAT decelerated to 7% YoY/31% YoY. The company guided a positive outlook for FY24.
  • Net cash increased to 271 mn HKD, representing 28% of market capitalization (990 mn HKD), as the company benefitted from positive working capital cycle changes. 
  • Water Oasis (1161 HK) declared a 7-cent dividend for H2 FY23, bringing the overall dividend for FY23 to 14 cents (9.6% div yield). 

Haier Smart Home (6690 HK): Further Expansion of Footprint

By Osbert Tang, CFA

  • Haier Smart Home (6690 HK)‘s acquisition of Carrier commercial refrigeration business is earnings accretive. It will also be strategically positive to its growth outlook. 
  • With net cash of Rmb17.3bn, HSH has no problem funding the deal internally. Instead of earning a single-digit return on cash, the business’ 9% earnings yield is attractive. 
  • The transaction will extend HSH’s application scenarios from household to commercial while elevating its competitiveness in Europe and allowing it to capture the B-end customers. 

WuXi AppTec (2359.HK/603259.CH) – How Bad Things Could Be?

By Xinyao (Criss) Wang

  • Recent business updates of WuXi Bio led to a decline in WuXi AppTec’s share price and changed investors’ expectations for CXO. Now is the time to adjust forecasts.
  • We analyzed the growth rate of various business of WuXi AppTec in 2024. In a neutral scenario, growth next year could fall short of management’s guidance.Reversal in 2025 is uncertain.
  • If WuXi AppTec “unexpectedly” receives blockbuster orders, which are large enough to hedge against the downward trend of WuXi AppTec’s other businesses, then it will help to change performance expectations.

LICHF: H2FY24 Guided to Be Strong

By Ankit Agrawal, CFA

  • LICHF reported a decent Q2FY24 led by a strong NIM (3.04%). Growth has been somewhat subdued due to technical issues, however, these have been resolved and October is tracking well.
  • LICHF reiterated its full-year FY24 NIM guidance at 2.6-2.8%. Credit cost, except for one-off item of INR 104cr in Q2FY24, continues to be below 50bp annualized.
  • Despite a subdued H1FY24, LICHF has maintained its FY24 AUM growth guidance to 10%+. This implies that LICHF can grow AUM at 5%+ QoQ over the next two quarters.

Marvell Industry Analyst Day

By Douglas O’Laughlin

  • Marvell reported earnings recently, and I wanted to mention that at least before I continued onwards because that is a good context-setting event for the industry day.

  • Revenue exceeded expectations, but the mix beneath the results was illustrative.

  • Datacenter revenue grew 20% QoQ, cloud over 30% QoQ; while networking was strong, they guided for a 40% QoQ decline, consistent with networking OEM results.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Macro: Avoiding a Lost Decade: China’s Real Estate Adjustment Reaches Critical Juncture in 2024 and more

By | Daily Briefs, Macro

In today’s briefing:

  • Avoiding a Lost Decade: China’s Real Estate Adjustment Reaches Critical Juncture in 2024
  • 2024 High Conviction Idea: Buy U.S. Financials
  • EM Fixed Income Focus: Only One Turtle Dove Is Needed for EM Assets
  • The Most Frothy Time of the Year?
  • 2024 High Conviction Idea: The Case for a Rotation Out of Japan into Hong Kong – Part 2
  • Interest Rates and Oil: Crossroads Ahead
  • Steno Signals #78 – Santa Powell Handing Out Gifts Even to the Naughty!


Avoiding a Lost Decade: China’s Real Estate Adjustment Reaches Critical Juncture in 2024

By Said Desaque

  • Japan endured years of economic stagnation due to an impaired banking system following the bursting its real estate bubble and some commentators currently fear a repeat experience in China.
  • Despite the potential for debt swaps with local government, regional banks will bear the brunt of loan restructuring to local government financing vehicles via higher loan-loss provisions.
  • The main of objective of central government in 2024 will be stabilising home sales in Tier-1 cities via easier policy measures. Bank lending to private property developers will remain tight.    

2024 High Conviction Idea: Buy U.S. Financials

By Cam Hui

  • We are making U.S. financials a high conviction buy idea for the following reasons
  • Positive macro backdrop from falling yields and steepening yield curve.
  • Sector shows strong technical strength and strong contrarian buy signals.

EM Fixed Income Focus: Only One Turtle Dove Is Needed for EM Assets

By At Any Rate

  • The Fed’s decision to potentially cut interest rates in June instead of July may have significant implications for emerging markets (EM) assets.
  • The shift in the Fed’s stance is proactive and not a response to a sudden downturn in data, suggesting a soft landing scenario for emerging markets.
  • This change in the Fed’s policy may alter the recommendations and views for next year, potentially leading to a more bullish outlook for EM assets.

This podcast is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only.


The Most Frothy Time of the Year?

By Cam Hui

  • The U.S. stock market appears to be undergoing a seasonal rally into year-end and January. Warning signs of froth are starting to appear and traders should exercise caution.
  • We believe stock prices may advance further into a possible blowoff top.
  • In particular, the market may be poised for a Gamestop-style short-covering rally. Hedge funds were caught offside in a crowded short when low-quality names began to rally.

2024 High Conviction Idea: The Case for a Rotation Out of Japan into Hong Kong – Part 2

By Rikki Malik

  • Risk reward favours a shift in allocation between these markets.
  • Hong Kong washed out from a sentiment, valuation and positioning perspective.
  • Minimal investor expectations  and continual disappointment  have set the stage for a rally in 2024.

Interest Rates and Oil: Crossroads Ahead

By Untying The Gordian Knot

  • US retail sales and inflation rates are retreating, and industrial activity is slowing.
  • Europe’s economic decline is accelerating compared to the US.
  • Oil prices are dipping in anticipation of weaker demand amidst a slowing economy signal.

Steno Signals #78 – Santa Powell Handing Out Gifts Even to the Naughty!

By Andreas Steno

  • Powell invited for a yuuuge risk asset party this week by allowing the market to continue to chase the narrative of material rate cuts in 2024.
  • This is (again) reminiscent of the 2006-2007 pause when the Fed allowed financial conditions to ease materially in the run-up to the recession.
  • During a hiking cycle, loads and loads of USDs are parked in cash-like setups due to a sudden better relative yield premium in almost risk-free structures.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Industrials: InterGlobe Aviation Ltd, Benefit One Inc and more

By | Daily Briefs, Industrials

In today’s briefing:

  • Interglobe Aviation (INDIGO IN | SELL | TP: INR2,513): Not Worth a King’s Ransom
  • Weekly Deals Digest (17 Dec) – Benefit One, Shinko Electric, Toyo, CPMC, Vinda, Hollysys, Rept
  • Last Week in Event SPACE: Benefit One, CPMC, Samsung C&T, Sands China, Shinko Electric, Hankook & Co


Interglobe Aviation (INDIGO IN | SELL | TP: INR2,513): Not Worth a King’s Ransom

By Mohshin Aziz

  • InterGlobe Aviation Ltd (INDIGO IN) (Indigo) has turnaround and is on path to achieve record profits in FY2024 on strong demand, stable FX and lower jet fuel prices 
  • However, engine problems will hurt capacity deployment in 4QFY24 and FY2025, and the engine manufacturer has been very vague and unreliable in presenting its remedial plans 
  • Share price near all-time high and valuations (PE, EV/EBITDAR) are expensive compared to global LCCs. TP of INR2,513 (14% DOWNSIDE) pegged to 15x FY2025 PE (top-end LCC cycle)  

Weekly Deals Digest (17 Dec) – Benefit One, Shinko Electric, Toyo, CPMC, Vinda, Hollysys, Rept

By Arun George


Last Week in Event SPACE: Benefit One, CPMC, Samsung C&T, Sands China, Shinko Electric, Hankook & Co

By David Blennerhassett


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Health Care: Shanghai Haoyuan Chemexpress, Boryung Pharmaceutical and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • China Healthcare Weekly (Dec.15)-BMS/Biokin $8.4B Eye-Popping Deal, NRDL Negotiation Result, Haoyuan
  • Boryung Pharmaceutical (003850 KS): Prescription Drugs Took a Breather in Q3; Poised to Rebound


China Healthcare Weekly (Dec.15)-BMS/Biokin $8.4B Eye-Popping Deal, NRDL Negotiation Result, Haoyuan

By Xinyao (Criss) Wang

  • 2023 NRDL negotiation results were released. We’re seeing the rules of NRDL renewal negotiations tilt toward innovative drugs, leading to lower price reduction, but there has been no fundamental change.
  • The record-breaking US$8.4 billion deal involving BMS and Sichuan Biokin Pharmaceutical (688506 CH) (SystImmune) is not without risk, though. We still recommend to remain rational.
  • The issue facing Shanghai Haoyuan Chemexpress (688131 CH) is higher revenue but lower margins. Valuation will likely experience further declines due to lock-up expiry and share reduction.

Boryung Pharmaceutical (003850 KS): Prescription Drugs Took a Breather in Q3; Poised to Rebound

By Tina Banerjee

  • In 3Q23, Boryung Pharmaceutical (003850 KS) reported 15% YoY growth in revenue to KRW208B, driven by 7% YoY growth in prescription drugs, the slowest growth in the last three years.
  • Prescription drug revenue growth slowed due to the huge shortfall in revenue from the diabetes drug Trulicity caused by supply shortage. We expect slowdown in Trulicity revenue is temporary.  
  • Despite losing patent protection in February 2023 on ARB monotherapy, Kanarb drug family is showing no fatigue due to increasing preference for combination drugs in the market.  

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief TMT/Internet: Taiwan Semiconductor (TSMC) – ADR, Hang Seng Index and more

By | Daily Briefs, TMT/Internet

In today’s briefing:

  • Taiwan Tech Weekly: AI Plays Weak Despite Strong Taiwan Tech Market Performance
  • EQD | Volatility Update: Weekly Review of Vol Changes and Best Trades-And Pivot!


Taiwan Tech Weekly: AI Plays Weak Despite Strong Taiwan Tech Market Performance

By Vincent Fernando, CFA

  • Overall, it was a strong week for Taiwan Tech. TSMC and Mediatek showed strong performances, as well as key names we like such as Yageo and Himax.
  • AI-Related Taiwan plays showed relative weakness. This weakness interestingly happened during a week when NVIDIA Corp (NVDA US) performed well.
  • According to insight provider Patrick Liao, MediaTek WiFi 7 chip competition is likely to become fierce in 2024.

EQD | Volatility Update: Weekly Review of Vol Changes and Best Trades-And Pivot!

By Simon Harris

  • Weekly summary of vol changes and moves across Global Markets
  • Analysing ATM volatility and skew changes over the last 5 days
  • We suggest a few trades to take advantage of the implied vol surfaces

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Industrials: InterGlobe Aviation Ltd, Benefit One Inc and more

By | Daily Briefs, Industrials

In today’s briefing:

  • Interglobe Aviation (INDIGO IN | SELL | TP: INR2,513): Not Worth a King’s Ransom
  • Weekly Deals Digest (17 Dec) – Benefit One, Shinko Electric, Toyo, CPMC, Vinda, Hollysys, Rept
  • Last Week in Event SPACE: Benefit One, CPMC, Samsung C&T, Sands China, Shinko Electric, Hankook & Co


Interglobe Aviation (INDIGO IN | SELL | TP: INR2,513): Not Worth a King’s Ransom

By Mohshin Aziz

  • InterGlobe Aviation Ltd (INDIGO IN) (Indigo) has turnaround and is on path to achieve record profits in FY2024 on strong demand, stable FX and lower jet fuel prices 
  • However, engine problems will hurt capacity deployment in 4QFY24 and FY2025, and the engine manufacturer has been very vague and unreliable in presenting its remedial plans 
  • Share price near all-time high and valuations (PE, EV/EBITDAR) are expensive compared to global LCCs. TP of INR2,513 (14% DOWNSIDE) pegged to 15x FY2025 PE (top-end LCC cycle)  

Weekly Deals Digest (17 Dec) – Benefit One, Shinko Electric, Toyo, CPMC, Vinda, Hollysys, Rept

By Arun George


Last Week in Event SPACE: Benefit One, CPMC, Samsung C&T, Sands China, Shinko Electric, Hankook & Co

By David Blennerhassett


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Financials: KE Holdings , NFT and more

By | Daily Briefs, Financials

In today’s briefing:

  • [KE Holdings Inc. (BEKE US, BUY, TP US$24.5) TP Change]: Policy Stimulus Drive up near Term Sales
  • The Year Ahead For Gaming 2024 (Executive Summary)


[KE Holdings Inc. (BEKE US, BUY, TP US$24.5) TP Change]: Policy Stimulus Drive up near Term Sales

By Eric Wen

  • Beijing and Shanghai laid out long waited stimulus policies on property market, include 1) lower property down payments ratio;2) lower mortgage loan rate;
  • 3) lower recognition standard for ordinary home. The key is to encourage households to add leverage.
  • We treat the financial stimulus as one-off positive shock to the home transaction markets in the two cities,  especially benefiting 1Q24 sales for Beike due to…

The Year Ahead For Gaming 2024 (Executive Summary)

By Gerryl Pay

  • Blockchain gaming peaks industry interest with unprecedented content quality. With the combined market cap of almost 200 leading projects being less than DOGE, there is ample room for future growth.
  • In 2023, 133 deals closed, securing $1.1B in funding, marking a 66% drop from 2022. Anticipating a reversal in the next ~6 months due to increased attention and capital.
  • High Web3 project costs drive competition for <1M gaming-inclined wallets. A battle for player liquidity will favor projects with versatile user bases, efficiently funneling between games for market dominance.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Consumer: Vinda International, Tongcheng Travel Holdings , Denso Corp and more

By | Consumer, Daily Briefs

In today’s briefing:

  • (Mostly) Asia-Pac Weekly Risk Arb Wrap: Sigma Health, Vinda, Outsourcing, Allkem, Costa, Hollysys
  • Index Rebalance & ETF Flow Recap: HSTECH, SIG/CWG, KQ150, REPT BATTERO
  • ECM Weekly (17th Dec 2023) – Toyota, Denso, Mankind, Axis, Merdeka, DOMS, India Shelter, Inox


(Mostly) Asia-Pac Weekly Risk Arb Wrap: Sigma Health, Vinda, Outsourcing, Allkem, Costa, Hollysys

By David Blennerhassett


Index Rebalance & ETF Flow Recap: HSTECH, SIG/CWG, KQ150, REPT BATTERO

By Brian Freitas

  • It was a busy week with rebalance implementations at the close of trading on Thursday in Korea and then across the region on Friday.
  • The SET 50 Index changes should be announced this week and the Yuanta TW Div+ ETF will continue to implement the changes till Thursday.
  • There were inflows to China ETFs during the week while there were big outflows from Korea Stock Exchange KOSPI 200 (KOSPI2 INDEX) ETFs.

ECM Weekly (17th Dec 2023) – Toyota, Denso, Mankind, Axis, Merdeka, DOMS, India Shelter, Inox

By Sumeet Singh

  • Aequitas Research puts out a weekly update on the deals that were covered by the team recently along with updates for upcoming IPOs.
  • A few large placements in India, along with Denso Corp (6902 JP) pricing, kept the market ticking this week.
  • In the IPO space, India saw a flurry of launches, as companies and banker try to cash-in on the market frenzy.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief South Korea: Boryung Pharmaceutical and more

By | Daily Briefs, South Korea

In today’s briefing:

  • Boryung Pharmaceutical (003850 KS): Prescription Drugs Took a Breather in Q3; Poised to Rebound


Boryung Pharmaceutical (003850 KS): Prescription Drugs Took a Breather in Q3; Poised to Rebound

By Tina Banerjee

  • In 3Q23, Boryung Pharmaceutical (003850 KS) reported 15% YoY growth in revenue to KRW208B, driven by 7% YoY growth in prescription drugs, the slowest growth in the last three years.
  • Prescription drug revenue growth slowed due to the huge shortfall in revenue from the diabetes drug Trulicity caused by supply shortage. We expect slowdown in Trulicity revenue is temporary.  
  • Despite losing patent protection in February 2023 on ARB monotherapy, Kanarb drug family is showing no fatigue due to increasing preference for combination drugs in the market.  

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars